Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service tumor & fibroid embolization cases in New York: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 11% on average (118 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 21 | 1,019 | 46% |
| 2020 | 15 | 807 | 48% |
| 2021 | 21 | 935 | 51% |
| 2022 | 19 | 1,052 | 53% |
| 2023 | 23 | 1,327 | 55% |
| 2024 | 22 | 1,661 | 57% |
| 2025 from claims | – | 2,195 2,015–2,323 | 58% |
| 2026 forecast | – | 2,400 2,111–2,769 | 58% |
| 2027 forecast | – | 2,612 2,233–3,112 | 59% |
| 2028 forecast | – | 2,842 2,371–3,480 | 59% |
| 2029 forecast | – | 3,092 2,525–3,877 | 60% |
| 2030 forecast | – | 3,363 2,694–4,309 | 60% |
Chemo- and radioembolization of liver tumors, uterine fibroid and other organ embolization (one code covers all). Professional codes (what the surgeon bills): CPT 37243.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 79% of the cases CMS names in New York; 11 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 4% inpatient hospital, 48% hospital outpatient, 1% surgery center, 47% office. The share outside the hospital has moved +40 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Surgery center | Office |
|---|---|---|---|---|
| 2026 · ~2,400 | ~78 | ~1,000 | ~36 | ~1,300 |
| 2027 · ~2,600 | ~77 | ~1,000 | ~41 | ~1,500 |
| 2028 · ~2,800 | ~80 | ~1,100 | ~45 | ~1,600 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: office about 57% (47% in 2025), hospital outpatient about 38% (48% in 2025).
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Pennsylvania | 19 | 908−0.7%/yr | −0.7%/yr | 0.7 | 27% | 1,830 in 2030+12%/yr |
| Massachusetts | 12 | 677+16%/yr | +16%/yr | 0.7 | 46% | 1,170 in 2030+9.5%/yr |
| New Jersey | 4 | 287+0.9%/yr | +0.9%/yr | 0.3 | 22% | 820 in 2030+19%/yr |
| Connecticut | 3 | 119−5.9%/yr | −5.9%/yr | 0.4 | 0% | 170 in 2030+6.1%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Breast biopsy & localization | 288 | 16,847+0.4%/yr | +0.4%/yr | 9.91.3× | 43% | 18,000 in 2030+1.1%/yr |
| Tumor ablation | 3 | 512+0.8%/yr | +0.8%/yr | 0.31.0× | 0% | 600 in 2030+2.7%/yr |
Tumor & fibroid embolization in every state, and its device makers · Every procedure market in New York · Every state · Compare with Pennsylvania
Boston Scientific leads with 31% of company spending on these surgeons in 2025, −1 pts on 2024.
In 2025, 21 companies reported engagement with New York’s surgeons worth $1.4M in consulting, speaking, meals and travel tied to these products, about $62K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 16 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.